UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism

The FDA told uniQure that its Phase I/II AMT-130 data versus an external natural-history control are insufficient to support a BLA and strongly recommended a prospective, randomized, double-blind sham surgery–controlled Phase III trial, effectively meaning uniQure will likely need a Phase III program. The decision follows prior alignment signals and three‑year positive data from the pivotal study, and prompted concern from Truist and Stifel while H.C. Wainwright flagged potential alternative paths; uniQure plans continued FDA engagement and a Type B meeting in Q2 to discuss Phase III design. The requirement raises the timeline, cost and regulatory risk for AMT-130 and is a material near-term negative for uniQure’s valuation and investor sentiment.

Analysis

Market structure: UniQure (QURE) is the clear loser—Phase 3/sham-surgery mandate materially delays any BLA, increasing time-to-revenue by 18–36 months and putting >30% downside risk on current equity valuation. Peer sentiment will spill to gene-therapy and rare-disease names (RGNX already hit), widening IV on small-cap biotech; IRON is neutral. Short-term patient supply for intracranial trials tightens, raising recruitment costs and giving larger, cash-rich pharmas negotiating leverage.

Risk assessment: Tail risks include a regulatory moratorium on intracranial sham designs or a failed Phase 3 that forces write-offs and dilution; both are low-probability but high-impact (equity → -70%, forced financing). Immediate (days) — sharp repricing and IV spikes; short-term (weeks–months) — capital raise/dilution risk and increased CDS/spread; long-term (12–36 months) — execution risk in a costly sham-controlled trial and manufacturing scale constraints for AAV. Hidden dependencies: patient advocacy/legal pressure, neurosurgeon capacity, and AAV supply could bottleneck timelines.

Trade implications: Favor idiosyncratic short on QURE via 1–2% portfolio short or buy 3-month ATM puts and a backstop 12-month put to capture delayed downside; use vertical put spreads to cap premium. Pair trade: short QURE vs long IBB (or long large-cap defensives like MRK/JNJ) to isolate regulatory idiosyncrasy. Enter within 5 trading days; exit/trim on either (a) Type B meeting yields explicit alternative path within 60 days or (b) successful Phase 3 enrollment progress by 12 months.

Contrarian angles: The market may be overselling—durable 3+ year data could still support accelerated approval via surrogate/real-world evidence, making >30% overshoot possible. Historical parallel: controversial regulatory setbacks (e.g., aducanumab-like political cycles) later resolved by alternative pathways or M&A; uniQure could become an acquisition target if priced deeply down. Unintended consequence: heavy selling increases takeover probability in 12–24 months at a favorable price for acquirers.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio short position in QURE within 5 trading days via borrow or buy 3-month ATM puts plus a 12-month put (20–30% OTM) as a hedge against a >30% downside in 6–12 months; use verticals to limit premium spend.
• Implement a pair trade: short QURE (notional X) vs long IBB (notional X) to isolate idiosyncratic FDA/regulatory risk; rebalance if QURE underperforms by >25% or if FDA signals an alternative path within 60 days.
• Rotate 2–4% of small-cap gene-therapy exposure into large-cap defensives: buy MRK or JNJ equal-weight exposure (reduce correlation risk) to lower portfolio beta to the regulatory news cycle over the next 6–12 months.
• Monitor and act on two binary catalysts: (1) Type B meeting outcome in Q2 — if FDA agrees to alternative endpoints, cover 50% of shorts within 10 trading days; (2) announcement of Phase 3 design or start — if a sham-controlled trial is confirmed, increase short position by up to 1% and prepare for a financing/dilution event within 3–6 months.